The Clinical Outcomes of Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Nationwide Registry Study of the Korean Multiple Myeloma Working Party (KMMWP)

被引：0
|
作者：
Lee, Ho Sup
Min, Chang-Ki
Lee, Je-Jung
Kim, Kihyun
Yoon, Sung-Soo
Kim, Inho
Bang, Soo-Mee
Kim, Jin Seok
Eom, Hyeon-Seok
Yoon, Dok Hyun
Lee, Yoojin
Shin, Ho-Jin
Park, Yong
Jo, Jae-Cheol
Lee, Won-Sik
Do, Young Rok
Mun, Yeung-Chul
Lee, Mark Hong
Kim, Hyo Jung
Kim, Sung-Hyun
Kim, Min Kyoung
Lim, Sung-Nam
Cho, Su-Hee
Park, Seong Kyu
Lee, Joon-ho
Lee, Jae Hoon
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3130
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Iida, Shinsuke
    Nagai, Hirokazu
    Kinoshita, Gen
    Miyoshi, Masafumi
    Robbins, Michael
    Pandya, Dimple
    Bleickardt, Eric
    Chou, Takaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 326 - 334
  • [32] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Shinsuke Iida
    Hirokazu Nagai
    Gen Kinoshita
    Masafumi Miyoshi
    Michael Robbins
    Dimple Pandya
    Eric Bleickardt
    Takaaki Chou
    International Journal of Hematology, 2017, 105 : 326 - 334
  • [33] REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA
    Ziff, M.
    Cheesman, S.
    Kyriakou, C.
    Mehta, A.
    Papanikolaou, X.
    Rabin, N.
    Wechalekar, A.
    Yong, K.
    Popat, R.
    HAEMATOLOGICA, 2017, 102 : 786 - 787
  • [34] Patient eligibility for lenalidomide/dexamethasone treatment in relapsed/refractory multiple myeloma
    Palumbo, A.
    Dimopoulos, M.
    San Miguel, J.
    Harousseau, J. L.
    Attal, M.
    Hussein, M.
    Knop, S.
    Ludwig, H.
    Sonneveld, P.
    von Lilienfeld-Toal, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 97 - 97
  • [35] Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
    Stewart, A. Keith
    Rajkumar, S. Vincent
    Dimopoulos, Meletios A.
    Masszi, Tamas
    Spicka, Ivan
    Oriol, Albert
    Hajek, Roman
    Rosinol, Laura
    Siegel, David S.
    Mihaylov, Georgi G.
    Goranova-Marinova, Vesselina
    Rajnics, Peter
    Suvorov, Aleksandr
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    San-Miguel, Jesus F.
    Ludwig, Heinz
    Wang, Michael
    Maisnar, Vladimr
    Minarik, Jiri
    Bensinger, William I.
    Mateos, Maria-Victoria
    Ben-Yehuda, Dina
    Kukreti, Vishal
    Zojwalla, Naseem
    Tonda, Margaret E.
    Yang, Xinqun
    Xing, Biao
    Moreau, Philippe
    Palumbo, Antonio
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02): : 142 - 152
  • [36] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
    Kobayashi, Tsutomu
    Kuroda, Junya
    Fuchida, Shin-ichi
    Kaneko, Hitomi
    Yagi, Hideo
    Shibayama, Hirohiko
    Tanaka, Hirokazu
    Kosugi, Satoru
    Uoshima, Nobuhiko
    Kobayashi, Masayuki
    Adachi, Yoko
    Ohta, Kensuke
    Ishii, Kazuyoshi
    Uchiyama, Hitoji
    Matsuda, Mitsuhiro
    Nakatani, Eiji
    Tsudo, Mitsuru
    Shimazaki, Chihiro
    Takaori-Kondo, Akifumi
    Nomura, Shosaku
    Matsumura, Itaru
    Taniwaki, Masafumi
    Kanakura, Yuzuru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (01) : 37 - 45
  • [37] Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone
    Ho Sup Lee
    Kihyun Kim
    Je-Jung Lee
    Sung-Soo Yoon
    Soo-Mee Bang
    Jin Seok Kim
    Hyeon-Seok Eom
    Dok Hyun Yoon
    Yoojin Lee
    Ho-Jin Shin
    Yong Park
    Jae-Cheol Jo
    Won Sik Lee
    Young Rok Do
    Yeung-Chul Mun
    Mark Hong Lee
    Hyo Jung Kim
    Sung-Hyun Kim
    Min Kyoung Kim
    Sung-Nam Lim
    Seong Kyu Park
    Jun Ho Yi
    Jae Hoon Lee
    Chang-Ki Min
    International Journal of Hematology, 2021, 113 : 81 - 91
  • [38] Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
    Harousseau, Jean-Luc
    Dimopoulos, Meletios A.
    Wang, Michael
    Corso, Alessandro
    Chen, Christine
    Attal, Michel
    Spencer, Andrew
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome B.
    Knight, Robert D.
    Weber, Donna M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (10): : 1738 - 1744
  • [39] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
    Tsutomu Kobayashi
    Junya Kuroda
    Shin-ichi Fuchida
    Hitomi Kaneko
    Hideo Yagi
    Hirohiko Shibayama
    Hirokazu Tanaka
    Satoru Kosugi
    Nobuhiko Uoshima
    Masayuki Kobayashi
    Yoko Adachi
    Kensuke Ohta
    Kazuyoshi Ishii
    Hitoji Uchiyama
    Mitsuhiro Matsuda
    Eiji Nakatani
    Mitsuru Tsudo
    Chihiro Shimazaki
    Akifumi Takaori-Kondo
    Shosaku Nomura
    Itaru Matsumura
    Masafumi Taniwaki
    Yuzuru Kanakura
    International Journal of Hematology, 2015, 101 : 37 - 45
  • [40] Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone
    Lee, Ho Sup
    Kim, Kihyun
    Lee, Je-Jung
    Yoon, Sung-Soo
    Bang, Soo-Mee
    Kim, Jin Seok
    Eom, Hyeon-Seok
    Yoon, Dok Hyun
    Lee, Yoojin
    Shin, Ho-Jin
    Park, Yong
    Jo, Jae-Cheol
    Lee, Won Sik
    Do, Young Rok
    Mun, Yeung-Chul
    Lee, Mark Hong
    Kim, Hyo Jung
    Kim, Sung-Hyun
    Kim, Min Kyoung
    Lim, Sung-Nam
    Park, Seong Kyu
    Yi, Jun Ho
    Lee, Jae Hoon
    Min, Chang-Ki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (01) : 81 - 91
12345